NCT04655118 2024-05-10Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic MastocytosisTelios Pharma, Inc.Phase 2 Unknown121 enrolled
NCT04333108 2023-05-06Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic TreatmentAB SciencePhase 3 Unknown140 enrolled